The nation of Zimbabwe has rejected a major US healthcare agreement valued at 367 million US dollars (£272m) over five years due to the United States' request for confidential biological samples.
This move came to light after a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "skewed".
An official spokesman later explained that the United States was requesting genetic material for research and commercial gain but refused to share the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further dialogue to find a agreement acceptable to all parties so the nation's vital HIV treatment initiative can be sustained.
Broader Background
Zimbabwe's decision comes after a similar situation in Kenya, where a high court blocked a similar health funding agreement following concerns were filed about the security of citizens' health data.
Since returning to office recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government deals to boost transparency and responsibility.
According to reports, Sixteen nations in Africa have so far signed these new agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, without any equivalent guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Put simply, our nation would provide the basic resources for medical research without any certainty that the resulting innovations would be accessible to our people should a future disease outbreak emerge."
Sovereignty and Global Health
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining structures previously established through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with future global health emergencies.
"This framework is intended to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "are not meant as hostility towards the US," he added.
"We encourage further discussions with our American counterparts on how subsequent collaboration might be designed in a way that respects the independence and dignity of both nations."
Health Experts Reaction
Medical experts said it acknowledged the government's concerns, but recommended that negotiations should continue given that a large portion of the nation's Aids initiatives depended on international support.
"Where specific concerns exist, including those involving data governance or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," the group said.
The halted deal highlights the ongoing debate between accepting vital international aid and protecting local interests in an increasingly data-driven world.